Literature DB >> 27746967

Losmapimod does not reduce cardiovascular events in patients with acute myocardial infarction.

Wilbert S Aronow1, Ryan K Kaple1.   

Abstract

Entities:  

Year:  2016        PMID： 27746967      PMCID： PMC5059299          DOI： 10.21037/jtd.2016.08.53

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

Review 1.  The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis.

Authors:  G Schett; J Zwerina; G Firestein
Journal:  Ann Rheum Dis       Date:  2007-09-07       Impact factor: 19.103

2.  Targeting inflammatory pathways for the treatment of cardiovascular disease.

Authors:  Paul M Ridker
Journal:  Eur Heart J       Date:  2013-11-07       Impact factor: 29.983

3.  Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.

Authors:  Michelle L O'Donoghue; Ruchira Glaser; Philip E Aylward; Matthew A Cavender; Adam Crisp; Keith A A Fox; Ian Laws; Jose L Lopez-Sendon; P Gabriel Steg; Pierre Theroux; Marc S Sabatine; David A Morrow
Journal:  Am Heart J       Date:  2015-02-23       Impact factor: 4.749

4.  Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

Authors:  Paul M Ridker; Jean MacFadyen; Peter Libby; Robert J Glynn
Journal:  Am J Cardiol       Date:  2010-06-10       Impact factor: 2.778

Review 5.  Anti-inflammatory therapies for cardiovascular disease.

Authors:  Paul M Ridker; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2014-05-26       Impact factor: 29.983

6.  Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

Authors:  Michelle L O'Donoghue; Eugene Braunwald; Harvey D White; Dylan P Steen; Mary Ann Lukas; Elizabeth Tarka; P Gabriel Steg; Judith S Hochman; Christoph Bode; Aldo P Maggioni; KyungAh Im; Jennifer B Shannon; Richard Y Davies; Sabina A Murphy; Sharon E Crugnale; Stephen D Wiviott; Marc P Bonaca; David F Watson; W Douglas Weaver; Patrick W Serruys; Christopher P Cannon; Dylan L Steen
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

7.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco Ah Fonseca; Jacques Genest; Antonio M Gotto; John Jp Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G Macfadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

8.  Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

Authors:  Michelle L O'Donoghue; Ruchira Glaser; Matthew A Cavender; Philip E Aylward; Marc P Bonaca; Andrzej Budaj; Richard Y Davies; Mikael Dellborg; Keith A A Fox; Jorge Antonio T Gutierrez; Christian Hamm; Robert G Kiss; František Kovar; Julia F Kuder; Kyung Ah Im; John J Lepore; Jose L Lopez-Sendon; Ton Oude Ophuis; Alexandr Parkhomenko; Jennifer B Shannon; Jindrich Spinar; Jean-Francois Tanguay; Mikhail Ruda; P Gabriel Steg; Pierre Theroux; Stephen D Wiviott; Ian Laws; Marc S Sabatine; David A Morrow
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

9.  Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

Authors:  Maysoon Elkhawad; James H F Rudd; Lea Sarov-Blat; Gengqian Cai; Richard Wells; L Ceri Davies; David J Collier; Michael S Marber; Robin P Choudhury; Zahi A Fayad; Ahmed Tawakol; Fergus V Gleeson; John J Lepore; Bill Davis; Robert N Willette; Ian B Wilkinson; Dennis L Sprecher; Joseph Cheriyan
Journal:  JACC Cardiovasc Imaging       Date:  2012-09

10.  Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.

Authors:  Joseph Cheriyan; Andrew J Webb; Lea Sarov-Blat; Maysoon Elkhawad; Sharon M L Wallace; Kaisa M Mäki-Petäjä; David J Collier; John Morgan; Zixing Fang; Robert N Willette; John J Lepore; John R Cockcroft; Dennis L Sprecher; Ian B Wilkinson
Journal:  Circulation       Date:  2011-01-24       Impact factor: 29.690
View more
  1 in total

Review 1.  Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018.

Authors:  Tingting Li; Sida Jiang; Bingwei Ni; Qiuji Cui; Qinan Liu; Hongping Zhao
Journal:  Int J Mol Sci       Date:  2019-09-12       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.